The Science Behind Vetana
To accomplish our mission of improving animal health, we are advancing efforts to transform treatment of chronic inflammatory diseases, starting with osteoarthritis, with a novel non-viral gene therapy.
Seeking a Solution
The key to treating chronic inflammation is re-establishing immune system homeostasis – restoring it back to balance. Yet, current treatments for chronic inflammatory diseases are often ineffective in doing so. Some are too potent and, when systemically delivered, lead to serious adverse events and widespread toxicity. Others simply mask the disease symptoms, rather than addressing the root source of pain and inflammation.
Current Options
Treatment options include steroid injections, non-steroidal anti-inflammatories (NSAIDS) and surgery. These options provide limited or, in many cases, ineffective relief from pain and improvement in mobility
Vetana's Investigational Therapy
Our lead therapeutic candidate is a species-specific, locally injectable plasmid DNA gene therapy expressing IL-10v, a proprietary modified variant of IL-10. This IL-10 variant significantly increases the duration of the effects of IL-10. Because the therapy is non-viral, there is also the potential for redosing.
Vetana is developing this therapy for multiple species including dogs, horses and cats.
